EA200800303A1 - Применение производных и аналогов тиазола при нарушениях, вызванных свободными жирными кислотами - Google Patents

Применение производных и аналогов тиазола при нарушениях, вызванных свободными жирными кислотами

Info

Publication number
EA200800303A1
EA200800303A1 EA200800303A EA200800303A EA200800303A1 EA 200800303 A1 EA200800303 A1 EA 200800303A1 EA 200800303 A EA200800303 A EA 200800303A EA 200800303 A EA200800303 A EA 200800303A EA 200800303 A1 EA200800303 A1 EA 200800303A1
Authority
EA
Eurasian Patent Office
Prior art keywords
fatty acids
free fatty
thiazole
analogues
derivatives
Prior art date
Application number
EA200800303A
Other languages
English (en)
Russian (ru)
Inventor
Бьёрн Эрикссон
Гвидо Курц
Кристиан Хедберг
Якоб Вестман
Original Assignee
Бетагенон Аб
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Бетагенон Аб filed Critical Бетагенон Аб
Publication of EA200800303A1 publication Critical patent/EA200800303A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EA200800303A 2005-07-21 2006-07-21 Применение производных и аналогов тиазола при нарушениях, вызванных свободными жирными кислотами EA200800303A1 (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US59562005P 2005-07-21 2005-07-21
SE0501721 2005-07-21
US74442206P 2006-04-07 2006-04-07
PCT/GB2006/002743 WO2007010281A2 (en) 2005-07-21 2006-07-21 Use of thiazole derivatives and analogues in disorders caused by free fatty acids

Publications (1)

Publication Number Publication Date
EA200800303A1 true EA200800303A1 (ru) 2008-10-30

Family

ID=37669179

Family Applications (2)

Application Number Title Priority Date Filing Date
EA200800303A EA200800303A1 (ru) 2005-07-21 2006-07-21 Применение производных и аналогов тиазола при нарушениях, вызванных свободными жирными кислотами
EA200800302A EA200800302A1 (ru) 2005-07-21 2006-07-21 Применение производных и аналогов тиазола при лечении рака

Family Applications After (1)

Application Number Title Priority Date Filing Date
EA200800302A EA200800302A1 (ru) 2005-07-21 2006-07-21 Применение производных и аналогов тиазола при лечении рака

Country Status (10)

Country Link
US (2) US20090156644A1 (enExample)
EP (2) EP1906955A2 (enExample)
JP (2) JP2009501776A (enExample)
KR (2) KR20080034436A (enExample)
AU (2) AU2006271383A1 (enExample)
CA (2) CA2615752A1 (enExample)
EA (2) EA200800303A1 (enExample)
IL (2) IL188031A0 (enExample)
NO (2) NO20076333L (enExample)
WO (2) WO2007010281A2 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102005024012A1 (de) * 2005-05-20 2006-11-23 Grünenthal GmbH Verwendung von 2,5-disubstituierten Thiazol-4-on-Derivaten in Arzneimitteln
WO2008065409A2 (en) * 2006-12-01 2008-06-05 Betagenon Ab Combination for use in the treatment of cancer, comprising tamoxifen or an aromatase inhibitor
WO2008090327A1 (en) * 2007-01-22 2008-07-31 Betagenon Ab New combination for use in the treatment of cancer
EP2136809A4 (en) * 2007-03-20 2012-01-04 Curis Inc INHIBITORS OF RAF KINASE CONTAINING A ZINC BINDING FRAGMENT
CN101274918A (zh) * 2007-03-30 2008-10-01 中国科学院上海药物研究所 一类取代五元杂环化合物,其制备方法和医学用途
AR067769A1 (es) * 2007-08-03 2009-10-21 Betagenon Ab Derivado de ditiazol para el tratamiento del cancer
MX2010003759A (es) 2007-10-09 2010-04-21 Merck Patent Gmbh Derivados de piridina utiles como activadores de glucocinasa.
CA2743756A1 (en) * 2007-11-15 2009-05-22 Musc Foundation For Research Development Inhibitors of pim protein kinases, compositions, and methods for treating cancer
KR100998572B1 (ko) * 2007-12-14 2010-12-07 한국생명공학연구원 단백질 포스파타제의 활성을 억제하는 페닐아미노티아졸론유도체 또는 이의 약학적으로 허용가능한 염을유효성분으로 함유하는 암 예방 및 치료용 조성물
WO2010073011A2 (en) 2008-12-23 2010-07-01 Betagenon Ab Compounds useful as medicaments
WO2010086613A1 (en) 2009-01-30 2010-08-05 Betagenon Ab Compounds useful as inhibitors as ampk
ES2567753T3 (es) 2009-07-08 2016-04-26 Baltic Bio Ab Derivados de 1,2,4-tiazolidin-3-ona y su uso en el tratamiento del cáncer
WO2011079036A1 (en) * 2009-12-22 2011-06-30 The Translational Genomics Research Institute Benzamide derivatives
WO2012118935A1 (en) 2011-03-03 2012-09-07 Proteotech Inc Compounds for the treatment of neurodegenerative diseases
US8722670B2 (en) * 2011-09-30 2014-05-13 Bristol-Myers Squibb Company Selective NR2B antagonists
WO2013108026A1 (en) 2012-01-17 2013-07-25 Baltic Bio Ab Thiadiazolone derivatives useful in the treatment of diabetes
CN104059060B (zh) * 2014-05-30 2017-08-01 西安交通大学 一种5‑(1h‑吲哚‑3‑亚甲基)‑1,3‑噻唑烷‑4‑酮类衍生物及其合成方法和应用
TW202122374A (zh) * 2019-08-15 2021-06-16 德商拜耳廠股份有限公司 製備２－（苯基亞胺基）－３－烷基－１，３－四氫噻唑－４－酮之方法
EP4448492A1 (en) 2021-12-17 2024-10-23 Reglagene, Inc. Compositions and methods of making and using small molecules in the treatment of cancer
US12215102B2 (en) 2023-02-28 2025-02-04 Reglagene, Inc. Compositions and methods for making and using small molecules for tubulin-targeted therapy in the treatment of cancers and related conditions

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3345374A (en) * 1962-09-04 1967-10-03 Bayer Ag Certain oxathiazole and dithiazole derivatives
US3671537A (en) * 1969-06-05 1972-06-20 Gyogyszerkutato Intezet Certain 3-(2,6-dichlorophenyl)-2-iminothiazolidines
US4103018A (en) * 1976-10-12 1978-07-25 Schering Corporation 2-[4-(Polyhalo-2-hydroxy-2-propyl)anilino]-2-oxazolin-4-ones and thiazolin-4-ones corresponding thereto
HU191408B (en) * 1984-04-25 1987-02-27 Egis Gyogyszergyar,Hu Process for preparing new imino-thiazolidine derivatives
DD246541A1 (de) * 1986-01-27 1987-06-10 Univ Halle Wittenberg Verfahren zur herstellung von 5-arylidenthiazolidin-4-onen
DD270072A1 (de) * 1988-03-14 1989-07-19 Univ Halle Wittenberg Verfahren zur herstellung von 5-aryliden- hoch 2-thiazolin-4-onen
US6353006B1 (en) * 1999-01-14 2002-03-05 Bayer Corporation Substituted 2-arylimino heterocycles and compositions containing them, for use as progesterone receptor binding agents
WO2004037250A1 (en) * 2002-10-23 2004-05-06 Beyond Genomics, Inc. 4-alkenylthiazoles comprising epoxide functionality, and methods of use thereof
WO2005082363A1 (en) * 2004-02-20 2005-09-09 Board Of Regents, The University Of Texas System Thiazolone compounds for treatment of cancer
JP2007535549A (ja) * 2004-04-30 2007-12-06 シェーリング　コーポレイション 神経ペプチドレセプターモジュレーター
BRPI0511390A (pt) * 2004-07-01 2007-12-04 Hoffmann La Roche tiazolinona quinolinas não-substituìdas
CA2574279A1 (en) * 2004-08-10 2006-02-23 Exelixis, Inc. Heterocyclic compounds as pharmaceutical agents
KR100890533B1 (ko) * 2004-10-14 2009-03-27 에프. 호프만-라 로슈 아게 Ｃｄｋ1 저해제로서의 퀴나졸리닐메틸렌 티아졸리논
CN100525929C (zh) * 2005-04-20 2009-08-12 郭文礼 喷水枪出水控制装置
JP2009500351A (ja) * 2005-07-04 2009-01-08 ドクター レディズ ラボラトリーズ リミテッド Ａｍｐｋアクチベータとしてのチアゾール誘導体

Also Published As

Publication number Publication date
IL188163A0 (en) 2008-03-20
US20090136472A1 (en) 2009-05-28
EP1906956A2 (en) 2008-04-09
CA2614327A1 (en) 2007-01-25
AU2006271383A1 (en) 2007-01-25
NO20076420L (no) 2008-04-09
KR20080032096A (ko) 2008-04-14
US20090156644A1 (en) 2009-06-18
WO2007010281A2 (en) 2007-01-25
CA2615752A1 (en) 2007-01-25
EP1906955A2 (en) 2008-04-09
KR20080034436A (ko) 2008-04-21
JP2009501775A (ja) 2009-01-22
WO2007010273A2 (en) 2007-01-25
JP2009501776A (ja) 2009-01-22
IL188031A0 (en) 2011-08-01
EA200800302A1 (ru) 2008-08-29
AU2006271375A2 (en) 2007-01-25
NO20076333L (no) 2008-04-01
WO2007010273A3 (en) 2007-05-10
WO2007010281A3 (en) 2007-06-07
AU2006271375A1 (en) 2007-01-25

Similar Documents

Publication Publication Date Title
EA200800303A1 (ru) Применение производных и аналогов тиазола при нарушениях, вызванных свободными жирными кислотами
EA200700860A1 (ru) (бифенил)карбоновые кислоты и их производные
RU2009126767A (ru) Производное 1-фенил-1-тио-d-глюцитола
EA200900066A1 (ru) Кристаллические сольваты и комплексы производных (1s)-1,5-ангидро-1-c-(3-((фенил)метил)фенил) -d-глюцитола с аминокислотами в качестве ингибиторов sglt2 для лечения диабета
EA201071045A1 (ru) Соединения оксадиазоантрацена для лечения диабета
EA200970296A1 (ru) Содержащие диариловый эфир соединения мочевины
BRPI0409624A (pt) 2-hidróxi-3-diaminoalcanos de benzamida
EA200870127A1 (ru) Полициклические производные аминокислот и способы их применения
CY1107956T1 (el) Χρηση υποκατεστημενων 2-αμινοτετραλινιων για την προληπτικη αντιμετωπιση της νοσου του παρκινσον
SE0301886D0 (sv) New use V
EA200870216A1 (ru) Амидо соединения и их применение в качестве лекарственных средств
EA200870193A1 (ru) Цитотоксические агенты, включающие новые производные томаймицина, и их терапевтическое применение
EA200802173A1 (ru) Производные терфенила для лечения болезни альцгеймера
EA201001595A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
SE0301882D0 (sv) New use I
BRPI0412851A (pt) benzamidazóis de n-metila-substituìdos
EA200700096A1 (ru) Производные 2-карбамид-4-фенилтиазола, способ их получения и их применение в терапии
EA200901573A1 (ru) Гетероарилзамещенные тиазолы
NO20076425L (no) Fremgangsmater for behandling av drug-resistent cancer
EA201070250A1 (ru) Противомикробный парентеральный состав
ATE539743T1 (de) Verfahren zur prävention und behandlung von ppar- vermittelten zuständen mit macelignan
EA200900780A1 (ru) Аналоги эпотилона, модифицированные в положениях c12-c13, как противораковые лекарственные средства
ATE552246T1 (de) Substituierte aryloxy-n- bicyclomethylacetamidverbindungen als vr1- antagonisten
EA200601846A1 (ru) Содержащие бензоксазины лекарственные комбинации для лечения заболеваний дыхательных путей
EA200900732A1 (ru) Кристаллическая калиевая соль аналогов липоксина а